MUSE™ offers millions of patients with reflux durable relief and the potential to eliminate the use of lifelong medication helping reduce healthcare costs

Medigus expects revenue from the MUSE system in 2014

OMER, Israel - Medigus Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and procedures, reveals additional details regarding its commercial strategy, including rebranding its flagship product MUSE™, formerly the SRS System. Through this strategy, CEO Chris Rowland shared his plans to reposition Medigus at the forefront of minimally invasive trans oral surgical procedures and place Medigus on track for ambitious commercial expansion.
"Our main objective continues to be the commercial launch of our flagship product, the MUSE™ system in key markets around the world," said Rowland. "MUSE™ provides physicians with an incision-less solution for the treatment of GERD compared to the traditional fundoplication surgeries, making it a more efficient and cost-effective procedure."

MUSE™, an intuitive endoscopic platform that consists of a single use surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder, performs a true surgical anterior fundoplication in a less invasive way, compared to other methods. This approach uses standard surgical staples with clinical data comparable to current surgical procedures. Furthermore, the system is a single-operator, out-patient procedure and offers patients the potential to eliminate lifelong medication, in addition to less hospital readmissions and hospitalizations, and reduced costs to the healthcare system.

In addition to the nearly 100,000 laparoscopic anti-reflux procedures performed in the U.S., the potential for MUSE™ in the U.S., which comprises about 20% of the global market, is roughly 24 million GERD patients. Medigus has identified a major "therapy gap" among this population, consisting of over 4 million people in the U.S., whom it believes will benefit most acutely from the MUSE™ system. These are patients who are not satisfied with their daily PPI medication to combat the symptoms of GERD, but have not decided on the more traditional surgical treatment.

Medigus' commercialization strategy is intended to generate initial MUSE™ system revenues in key markets during 2014. The strategy will focus on the following areas:

Maintaining existing FDA and CE approvals;
Pursuing clinical and peer-review publication goals to increase credibility and physician awareness while promoting insurance reimbursement recognition;

More HCB News